Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease
that can cause intense pain episodes. Hemoglobin SCD (HbSC) is a form of SCD that is
characterized by dense red blood cells. The purpose of this study is to evaluate the safety
and effectiveness of hydroxyurea and magnesium pidolate, alone and combined, at reducing red
blood cell density and the frequency of pain episodes in people with HbSC.